Transparency Council meeting: allergies, TNP and prevention programs

The agenda includes:

1. Preparation of a position paper on the evaluation of the drug Winrevair (sotatercept) under drug program B.31 "Treatment of pulmonary arterial hypertension (TNP) (ICD-10: I27, I27.0)".
2. Preparation of an opinion on recommended medical technologies and activities carried out under the health policy program:
   - "Prevention of chronic back pain".
3. Preparation of an opinion on recommended medical technologies and activities carried out under the health policy program:
   - "Prevention and early detection of rheumatoid arthritis".
4. Preparation of an opinion on the draft health policy program of the local government unit:
   - "Program for prevention of depressive disorders among adolescents in the Municipality of New Tomyśl for 2025-2029".
5. Preparation of an opinion on the draft health policy program of the local government unit:
   - "Health policy program for medical rehabilitation of residents of the municipality of Zary for 2026-2029".
6. Preparation of an opinion for the active substance Levocetirizini dihydrochloridum in the indications:
   - food allergy - in patients over 6 months of age,
   - anaphylactic reaction manifested by urticaria or Quincke's angioedema - in patients over 6 months of age.
7. Preparation of an opinion for the active substance Cetirizinum in the indications:
   - food allergy - in patients over 6 months of age,
   - anaphylactic reaction manifested by urticaria or Quincke's angioedema - in patients over 6 months of age.
8. Preparation of an opinion for the active substance Loratadinum in the indications:
   - food allergy - in patients over 2 years of age,
   - anaphylactic reaction manifested by urticaria or Quincke's angioedema - in patients over 2 years of age.

Source: AOTMiT